Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -7.92
- Piotroski Score 5.00
- Grade Buy
- Symbol (OPTN)
- Company OptiNose, Inc.
- Price $0.39
- Changes Percentage (-10.74%)
- Change -$0.05
- Day Low $0.38
- Day High $0.45
- Year High $2.10
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $3.00
- High Stock Price Target $5.00
- Low Stock Price Target $1.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.27
- Trailing P/E Ratio -3.93
- Forward P/E Ratio -3.93
- P/E Growth -3.93
- Net Income $-35,483,000
Income Statement
Quarterly
Annual
Latest News of OPTN
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
OptiNose Inc (OPTN) Q3 2024 Earnings Call Highlights: Revenue Growth Amid Revised Guidance
Full year 2024 operating expenses guidance revised to $90-$93 million. CFO explains conservative Q4 guidance due to inventory stocking impact in Q3. CEO notes most insurance plans updated coverage for...
By Yahoo! Finance | 5 days ago
